
The Market’s Roller Coaster: Discover the Stocks Defying the Downturn
Regeneron Pharmaceuticals saw a significant surge, gaining 4% per share, driven by promising results from a joint trial with Sanofi for Dupixent, targeting a severe autoimmune disease. Biogen emerged as a value play with its stock rising due to competitive valuation and